Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.
Inflammation
Machine learning
Metabolic syndrome
Precision medicine
Psychosis
Schizophrenia
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
25
02
2022
accepted:
26
02
2022
entrez:
26
4
2022
pubmed:
27
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments. A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors. Of the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS. We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific "immuno-metabolic" profile. This may help to design tailored treatments for this subgroup of patients with both psychotic disorders and MetS, taking one more step towards precision medicine in psychiatry.
Sections du résumé
Background
UNASSIGNED
Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments.
Method
UNASSIGNED
A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors.
Results
UNASSIGNED
Of the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS.
Conclusion
UNASSIGNED
We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific "immuno-metabolic" profile. This may help to design tailored treatments for this subgroup of patients with both psychotic disorders and MetS, taking one more step towards precision medicine in psychiatry.
Identifiants
pubmed: 35469211
doi: 10.1016/j.bbih.2022.100436
pii: S2666-3546(22)00026-6
pmc: PMC9034311
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100436Investigateurs
F Berna
(F)
E Haffen
(E)
M Leboyer
(M)
P M Llorca
(PM)
F Schürhoff
(F)
V Barteau
(V)
S Bensalem
(S)
O Godin
(O)
H Laouamri
(H)
K Souryis
(K)
M Leboyer
(M)
I Offerlin-Meyer
(I)
B Pignon
(B)
F Schürhoff
(F)
A Szöke
(A)
B Aouizerate
(B)
A Deloge
(A)
D Misdrahi
(D)
E Vilà
(E)
O Blanc
(O)
I Chéreau
(I)
H Denizot
(H)
R M Honciuc
(RM)
D Lacelle
(D)
P M Llorca
(PM)
S Pires
(S)
C Dubertret
(C)
J Mallet
(J)
C Portalier
(C)
J Dubreucq
(J)
C Fluttaz
(C)
F Gabayet
(F)
C Roman
(C)
G Chesnoy-Servanin
(G)
T D'Amato
(T)
J M Dorey
(JM)
R Rey
(R)
A Vehier
(A)
C Lançon
(C)
C Faget
(C)
E Metairie
(E)
P Peri
(P)
F Vaillant
(F)
L Boyer
(L)
G Fond
(G)
F Berna
(F)
P Vidailhet
(P)
A Zinetti-Bertschy
(A)
D Capdevielle
(D)
H Yazbek
(H)
S Esselin
(S)
M Jarroir
(M)
C Passerieux
(C)
M Urbach
(M)
Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
All authors declare that they have no competing interests.
Références
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8732-7
pubmed: 11447288
J Clin Endocrinol Metab. 2018 Jan 1;103(1):148-157
pubmed: 29053810
Lancet Psychiatry. 2015 Mar;2(3):258-270
pubmed: 26359903
Clin Immunol. 2012 Sep;144(3):190-9
pubmed: 22836084
Depress Anxiety. 2016 Aug;33(8):754-64
pubmed: 27120696
Schizophr Res. 2016 Feb;170(2-3):290-300
pubmed: 26794596
J Clin Psychiatry. 2018 Sep 18;79(6):
pubmed: 30257079
Nat Commun. 2021 Feb 24;12(1):1285
pubmed: 33627652
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Schizophr Res. 2019 Jul;209:193-197
pubmed: 31118157
Endocr Connect. 2017 May;6(4):278-288
pubmed: 28420718
Cytokine X. 2020 Dec 21;3(1):100050
pubmed: 33604566
Dialogues Clin Neurosci. 2018 Mar;20(1):63-73
pubmed: 29946213
Int J Med Sci. 2016 Jan 01;13(1):25-38
pubmed: 26816492
Pharmaceuticals (Basel). 2021 May 09;14(5):
pubmed: 34065135
J Biosci. 2018 Jun;43(2):321-327
pubmed: 29872020
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Front Mol Neurosci. 2016 Mar 22;9:16
pubmed: 27047333
Int J Obes Relat Metab Disord. 2002 Jan;26(1):137-41
pubmed: 11791159
World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
Cell Metab. 2012 May 2;15(5):635-45
pubmed: 22560216
Cell. 2010 Mar 19;140(6):900-17
pubmed: 20303879
J Psychiatr Res. 2019 Oct;117:31-37
pubmed: 31276836
Neuroimage. 2011 Apr 15;55(4):1519-27
pubmed: 21167288
Clin Dermatol. 2018 Jan - Feb;36(1):14-20
pubmed: 29241747
Lancet Psychiatry. 2015 May;2(5):452-464
pubmed: 26360288
Front Psychiatry. 2020 Feb 20;11:46
pubmed: 32153436
Curr Pharm Des. 2016;22(8):963-77
pubmed: 26667000
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Psychoneuroendocrinology. 2015 Jun;56:143-7
pubmed: 25827958
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:89-94
pubmed: 29778547
Biol Psychiatry. 2011 Oct 1;70(7):663-71
pubmed: 21641581
Curr Opin Psychiatry. 2012 Mar;25(2):83-8
pubmed: 22249081
Neuropsychiatr Dis Treat. 2013;9:941-6
pubmed: 23882141
Actas Esp Psiquiatr. 2013 Jan-Feb;41(1):17-26
pubmed: 23440532
Eur Psychiatry. 2015 Sep;30(6):728-35
pubmed: 26072427
Lik Sprava. 2007 Jul-Sep;(5-6):46-9
pubmed: 18416164
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Neuroendocrinology. 2017;104(4):382-397
pubmed: 27165273
Schizophr Res. 2015 Oct;168(1-2):388-94
pubmed: 26255568
Indian J Med Res. 2014 Aug;140(2):238-43
pubmed: 25297357
Andrology. 2017 Jan;5(1):23-30
pubmed: 27813377
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Brain Behav Immun. 2021 Mar;93:331-334
pubmed: 33378714
Clin Nutr. 2014 Aug;33(4):596-602
pubmed: 24315622
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):408-416
pubmed: 28760387
PLoS One. 2011;6(5):e19590
pubmed: 21611123
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Psychol Med. 2018 May;48(7):1102-1110
pubmed: 28889804
Brain Behav Immun. 2013 Jul;31:82-9
pubmed: 22982547
Mol Neurobiol. 2017 Dec;54(10):8170-8178
pubmed: 27900676
Br J Psychiatry Suppl. 1993 Dec;(22):39-44
pubmed: 8110442
Clin Exp Med. 2015 Nov;15(4):433-8
pubmed: 25427620
JAMA Psychiatry. 2017 Mar 01;74(3):261-269
pubmed: 28097367
Psychopharmacology (Berl). 2015 Jan;232(1):165-72
pubmed: 24958229
Br J Nutr. 2004 Sep;92(3):347-55
pubmed: 15469638
Psychiatr Danub. 2014 Sep;26(3):214-9
pubmed: 25191767
Psychosom Med. 2020 Nov/Dec;82(9):838-849
pubmed: 32947580
Prev Sci. 2007 Sep;8(3):206-13
pubmed: 17549635
Psychol Med. 2016 Nov;46(15):3219-3230
pubmed: 27604840
Schizophr Res. 2010 May;118(1-3):211-7
pubmed: 20189773
Schizophr Res. 2005 Dec 1;80(1):19-32
pubmed: 16137860
Am J Psychiatry. 2003 Feb;160(2):284-9
pubmed: 12562574
Diabet Med. 2007 May;24(5):481-5
pubmed: 17381506
Schizophr Res. 2017 Mar;181:38-42
pubmed: 27751654
Curr Genomics. 2018 Nov;19(7):630-666
pubmed: 30386174
Am J Psychiatry. 1994 Aug;151(8):1132-6
pubmed: 8037246
Brain Behav Immun. 2020 Aug;88:174-183
pubmed: 32272220
Br J Psychiatry. 2017 Dec;211(6):339-349
pubmed: 28982658
Schizophr Bull. 2013 Mar;39(2):306-18
pubmed: 22207632
Schizophr Bull. 2015 Sep;41(5):1162-70
pubmed: 25829375
Int J Public Health. 2013 Dec;58(6):855-64
pubmed: 23999626
Diabetologia. 2015 Oct;58(10):2361-70
pubmed: 26152662
Acta Psychiatr Scand. 2020 Feb;141(2):169-171
pubmed: 31705669
Pharmacol Res. 2015 Nov;101:74-85
pubmed: 26218604
Metabolism. 2013 Nov;62(11):1543-52
pubmed: 23932846
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
Brain Behav Immun. 2018 Jul;71:28-36
pubmed: 29730395
Br J Clin Psychol. 2002 Nov;41(Pt 4):417-22
pubmed: 12437796
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
World Psychiatry. 2015 Oct;14(3):339-47
pubmed: 26407790
Metab Syndr Relat Disord. 2015 Oct;13(8):336-42
pubmed: 26038987